Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
61
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,218.24 | 26.05 | -0.32% |
| DAX 40 | 24,759.05 | 185.90 | -0.75% |
| Dow JONES (US) | 50,866.78 | 695.15 | -1.35% |
| FTSE 100 | 10,368.05 | 7.73 | 0.07% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 25,709.43 | 1,121.53 | -4.18% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,383.74 | 200.57 | -2.64% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |